

Daily evidence digest

2 July 2021

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Phase 3 trial of Novavax, age-related immune response to Pfizer vaccine, telenursing home care and COVID-19

Peer reviewed journals articles:

- A phase 3 trial on the safety and efficacy of the Novavax vaccine [here](#)
- A narrative review on allogenic mesenchymal stem cells in treating severe COVID-19 [here](#)
- Observational studies on:
 - Age-related immune response heterogeneity to Pfizer vaccine [here](#)
 - Prevention and attenuation of COVID-19 with the Pfizer and Moderna vaccines [here](#)
 - Sex-specific risk factors and clinical outcomes in COVID-19 [here](#)
 - The autumnal lockdown and the decrease in SARS-CoV-2 circulation in France [here](#)
 - Performance of SARS-CoV-2 lateral flow antigen tests [here](#)
 - Pfizer vaccine effectiveness in patients with hematologic malignancy [here](#)
 - Aerosol generation during oesophago-gastro-duodenoscopy [here](#)
- Modelling studies on:
 - Introductions and persistence in COVID-19 resurgence in Europe [here](#)
 - Airborne infection risk during open-air cardiopulmonary resuscitation [here](#)
- Qualitative studies on:
 - Learning from minor injury care restructure during COVID-19 [here](#)
 - Telenursing home care and COVID-19 [here](#)
- An editorial on COVID-19, equity, and inclusiveness [here](#)
- Commentary on:
 - The “GOTVax” (Get Out The Vax) mobile COVID-19 vaccine program campaign [here](#)
 - Confronting post-acute COVID-19 syndrome [here](#)
 - The COVID-19 ‘wicked problem’ and public health ethics [here](#)
 - How long COVID-19 immunity lasts [here](#)

Letters and correspondence discussed:

- A randomised clinical trial of targeted messaging to improve return to in-person visits [here](#)
- COVID-19 in recipients of allogeneic stem cell transplantation [here](#)
- Implications of the second wave of COVID-19 in India [here](#)

Pre-peer review articles featured:

- Persistent symptoms and residual abnormal functioning following acute COVID-19 [here](#)
- The resurgence of Delta variant (B.1.617.2) in India [here](#)
- Comparative evaluation of the transmissibility of SARS-CoV-2 variants of concern [here](#)
- Immunogenicity of COVID-19 vaccination in immunocompromised patients [here](#)

Guidance and reports

- The World Health Organization published updates of its:
 - Weekly epidemiological report on COVID-19 [here](#)
 - COVID-19 vaccine tracker [here](#)

News and blogs

- The countries that have mandatory vaccination for health workers [here](#)
- The third vaccine dose boosts immune response but may not be needed [here](#)
- Events pilot finds “no substantial outbreaks,” but experts point to gaps in evidence [here](#)
- Upgrading face masks to FFP3 respirators cuts infection risk [here](#)
- GP staff have faced threats and abuse during the vaccination program in the UK [here](#)
- Artificially intelligent nanopore for rapid SARS-CoV-2 testing [here](#)

[Click here](#) to subscribe to the daily evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on [COVID-19 transmission](#), SARS-CoV-2 [vaccines](#), and [variants](#) of concern, and [post-acute sequelae of COVID-19 \(PASC\)](#).